Three Biotech Stocks That Have Triggered Alerts: ABEO, IPCI, And VBIO


Three stocks that are trading sharply higher in early Tuesday trading include Abeona (ABEO), Intellipharmaceutics (IPCI) and Vitality Biopharma (VBIO). Trades Ideas provided real-time price alerts on these closely-watched CNA Finance stocks.


ABEO is trading higher by 4.7%, breaching the $5.00 level for the first time in two weeks. No specific news for ABEO has been published this morning, but the stock is trading higher on solid buying interest with the share price now trading at $5.05 (10:25).

ABEO is a gene therapy company developing a gene therapy solution to treat Sanfilippo Syndrome and EB.


Shares of IPCI are trading higher by almost 3%, breaching the $3.00 resistance level faced during the prior two weeks. IPCI recently announced that both the U.S. and Canadian governments have awarded IPCI a patent protecting their PODRAS technology, a technology that produces abuse-deterrent compounds and drugs designed to curb intentional misuse of prescribed medications, especially in the opiate class.

IPCI is further waiting to hear from the FDA regarding its NDA that was filed in December for Rexista, its abuse-deterrent oxycodone compound. Shares currently sit at $3.04 (10:28), with strong buying interest in early trading.


Vitality Biopharma is ripping higher by over 36% on strong volume, with shares now selling at $3.19 (10:33), down 12¢ from the high of the day. CNA Finance covered VBIO last week, and shares have seen a sharp rise since our initial publication, trading over 110% higher since December 21st.

VBIO released news last week that the DEA has approved VBIO to use cannabis compounds in their on-going clinical research to treat IBD and NBS.

CNA Finance will keep followers appraised of any new alerts and company-specific news as it occurs.

Disclosure: This article was written by Kenny Soulstring, and it reflects my own opinions and unique articulation. This article is not intended to offer investing advice, guarantee 100% accurate predictions or to be interpreted as providing a personal recommendation. What I can guarantee, though, is accurate research, thoughtful analysis and an enthusiasm about any stock that I cover.

While I seek to uncover emerging companies that I feel have true value and potential, it’s important that investors assign an appropriate time horizon to each of their investments, understanding that emerging companies need time to mature.

I wrote this article myself and it includes my own research and expresses my own opinions. I am not receiving compensation for it (other than from CNA Finance). I have no business relationship with any company whose stock is mentioned in this article.

Additional Disclosure: I am long ABEO, IPCI and may purchase additional shares within the next 72 hours. I have no position in VBIO and no plans to initiate any positions within the next 72 hours.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

[Image Courtesy of Flickr]


Please enter your comment!
Please enter your name here